## Abstract Despite all recent advances in symptomatic therapy Parkinson's disease (PD) continues to be a relentlessly progressive neurodegenerative disorder. Therefore therapies that will slow or hold disease progression are a major medical unmet need in PD. Clinical measures of disease progressio
Rate of clinical progression in Parkinson's disease. A prospective study
✍ Scribed by Anette Schrag; Richard Dodel; Annika Spottke; Bernhard Bornschein; Uwe Siebert; Niall P. Quinn
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 79 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate of clinical progression of PD in a clinic‐based sample of 145 patients over 1 year and in a community‐based sample of 124 patients over 4 years. Depending on the sample and clinical scale used, mean deterioration of motor and disability scores ranged from 2.4 to 7.4% of the maximum possible score per year, and standard deviations indicated that there was considerable variability of progression rates between individuals. The progression of motor scores decreased with follow‐up over 4 years and significantly decreased in more advanced disease stages. Deterioration of disability scores did not differ between disease stages; this may reflect the increasing rate of disease complications, which contribute to increasing disability in addition to motor impairment alone, in more advanced disease. Thus, motor fluctuations, hallucinations, depression, memory problems, and bladder symptoms were all reported more often at follow‐up in the community‐based sample (all P < 0.01), and dyskinesias, motor fluctuations, falls, and hallucinations were more common and cognitive and depression scores worse in higher disease stages in the clinic‐based sample (all P < 0.001). We conclude that progression of motor scores in PD decreases with advancing disease in PD. However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology. © 2007 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract Pain sensitivity in Parkinson's disease is known to be altered in an L‐dopa‐dependent manner with increased spinal nociception and experimental pain perception in the medication‐defined “off” state. As Parkinson's disease‐related pain can be an early symptom in Parkinson's disease, the
## Abstract The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[^18^F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first
## Abstract Parkinsonian speech or hypokinetic dysarthria results from a multidimensional impairment of phonation, articulation, and prosody. Although the dysprosody in Parkinson's disease (PD) is well described (alterations in speech rate and pause time, speech intensity and pitch variation), litt